Reviewing CEL-SCI Corporation (CVM)’s and Sutro Biopharma Inc. (NASDAQ:STRO)’s results

As Biotechnology companies, CEL-SCI Corporation (NYSEAMERICAN:CVM) and Sutro Biopharma Inc. (NASDAQ:STRO) are our subject to compare. And more specifically their analyst recommendations, profitability, risk, dividends, institutional ownership, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
CEL-SCI Corporation N/A 337.27 24.42M -1.24 0.00
Sutro Biopharma Inc. 38.42M 7.02 35.32M -2.21 0.00

Demonstrates CEL-SCI Corporation and Sutro Biopharma Inc. earnings per share (EPS), gross revenue and valuation.

Profitability

Table 2 shows us the return on assets, net margins and return on equity of both companies.

Net Margins Return on Equity Return on Assets
CEL-SCI Corporation 0.00% 0% -97.4%
Sutro Biopharma Inc. -91.93% 0% 0%

Liquidity

The Current Ratio and a Quick Ratio of CEL-SCI Corporation are 1.3 and 1.2. Competitively, Sutro Biopharma Inc. has 3.5 and 3.5 for Current and Quick Ratio. Sutro Biopharma Inc.’s better ability to pay short and long-term obligations than CEL-SCI Corporation.

Institutional & Insider Ownership

The shares of both CEL-SCI Corporation and Sutro Biopharma Inc. are owned by institutional investors at 8.8% and 75.3% respectively. Insiders held roughly 5.1% of CEL-SCI Corporation’s shares. Competitively, 8.5% are Sutro Biopharma Inc.’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
CEL-SCI Corporation -7.07% -9.93% -19.82% 3.14% 44.51% -8.36%
Sutro Biopharma Inc. -9.77% -14.46% -12.05% 0% 0% 0.33%

For the past year CEL-SCI Corporation had bearish trend while Sutro Biopharma Inc. had bullish trend.

CEL-SCI Corporation engages in the research and development of drugs and vaccines. Its lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer. The companyÂ’s Multikine is also used in a Phase I study with the Naval Medical Center, San Diego under a cooperative research and development agreement in HIV/HPV co-infected men and women with peri-anal warts. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.